Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15 | $18 | $15 | $17 |
| % Growth | -17.4% | 22.7% | -12% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $15 | $18 | $15 | $17 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $24 | $27 | $28 | $28 |
| G&A Expenses | $10 | $10 | $11 | $13 |
| SG&A Expenses | $10 | $10 | $11 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34 | $37 | $39 | $41 |
| Operating Income | -$18 | -$19 | -$25 | -$24 |
| % Margin | -121.6% | -103.2% | -164.3% | -138.8% |
| Other Income/Exp. Net | -$0 | $1 | $1 | $1 |
| Pre-Tax Income | -$19 | -$18 | -$24 | -$23 |
| Tax Expense | $0 | $0 | -$1 | -$0 |
| Net Income | -$19 | -$18 | -$23 | -$22 |
| % Margin | -123.6% | -99.7% | -151.7% | -131.4% |
| EPS | -0.87 | -0.85 | -1.06 | -1.05 |
| % Growth | -2.4% | 19.8% | -1% | – |
| EPS Diluted | -0.87 | -0.85 | -1.06 | -1.05 |
| Weighted Avg Shares Out | 21 | 21 | 21 | 21 |
| Weighted Avg Shares Out Dil | 21 | 21 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$16 | -$15 | -$21 | -$20 |
| % Margin | -107.6% | -84.1% | -140.9% | -117.1% |